Johnson & Johnson: To proactively delay rollout of vaccine in Europe
|Having heard from the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), Johnson & Johnson came out with the official announcement, during early Wednesday in Asia, suggesting a delay in vaccine rollout in Europe.
The drugmaker also said that it is aware of an extremely rare disorder caused by its vaccine.
“To pause vaccinations in all vaccine clinical trials,” said Johnson & Johnson further.
It’s worth mentioning that all 50 US states have stopped the use of Johnson & Johnson's COVID-19 vaccine on the CDC and the FDA recommendations.
FX implications
Following the update, S&P 500 Futures eases to 4,132.38, down 0.05%, after the Wall Street benchmark refreshed record top.
Also read: US calls for pause on Johnson & Johnson vaccine after clotting cases
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.